StockMacro
Company, fund or insider

Help

Menu

Fulcrum Therapeutics

$3.69 -45% in 6 monthsMarket cap $281.8M

FULC on XNAS, Health Care, Fulcrum Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 67% in 12 months as losses reached $76.3M, while cash stands at $116.4M.

  • WatchShort interest 8.4% of shares, down 4.7% on the prior report

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Industry
Pharmaceutical preparations (Health Care)
Employees
55
Website
fulcrumtx.com
Listed
Nasdaq, US
Last results
27 Apr 2026
Next results
no estimate
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $10.9M.
Quarter to 31 Dec 2021: revenue $5.1M, net income -$23.5MQuarter to 31 Dec 2021: revenue $5.1M, net income -$23.5MQuarter to 31 Mar 2022: revenue $2.6M, net income -$25.9MQuarter to 31 Mar 2022: revenue $2.6M, net income -$25.9MQuarter to 30 Jun 2022: revenue $1.9M, net income -$34.1MQuarter to 30 Jun 2022: revenue $1.9M, net income -$34.1MQuarter to 30 Sep 2022: revenue $1.2M, net income -$23.7MQuarter to 30 Sep 2022: revenue $1.2M, net income -$23.7MQuarter to 31 Dec 2022: revenue $685K, net income -$26.1MQuarter to 31 Dec 2022: revenue $685K, net income -$26.1MQuarter to 31 Mar 2023: revenue $295K, net income -$24.8MQuarter to 31 Mar 2023: revenue $295K, net income -$24.8MQuarter to 30 Jun 2023: revenue $880K, net income -$23.8MQuarter to 30 Jun 2023: revenue $880K, net income -$23.8MQuarter to 30 Sep 2023: revenue $759K, net income -$24.0MQuarter to 30 Sep 2023: revenue $759K, net income -$24.0MQuarter to 31 Dec 2023: revenue $871K, net income -$24.8MQuarter to 31 Dec 2023: revenue $871K, net income -$24.8MQuarter to 31 Mar 2024: revenue $0, net income -$26.9MQuarter to 31 Mar 2024: revenue $0, net income -$26.9MQuarter to 30 Jun 2024: revenue $80.0M, net income $55.4MQuarter to 30 Jun 2024: revenue $80.0M, net income $55.4MQuarter to 30 Sep 2024: revenue $0, net income -$21.7MQuarter to 30 Sep 2024: revenue $0, net income -$21.7MQuarter to 31 Dec 2024: revenue $0, net income -$16.6MQuarter to 31 Dec 2024: revenue $0, net income -$16.6MQuarter to 31 Mar 2025: revenue –, net income -$17.7MQuarter to 30 Jun 2025: revenue $0, net income -$17.3MQuarter to 30 Jun 2025: revenue $0, net income -$17.3MQuarter to 30 Sep 2025: revenue $0, net income -$19.6MQuarter to 30 Sep 2025: revenue $0, net income -$19.6MQuarter to 31 Dec 2025: revenue $0, net income -$20.3MQuarter to 31 Dec 2025: revenue $0, net income -$20.3MQuarter to 31 Mar 2026: revenue –, net income -$18.9MQuarter to 30 Jun 2026: revenue –, net income -$26.2MQuarter to 30 Sep 2026: revenue –, net income -$10.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $80.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$10.9M
30 Jun 2026–-$26.2M
31 Mar 2026–-$18.9M
31 Dec 2025$0-$20.3M
30 Sep 2025$0-$19.6M
30 Jun 2025$0-$17.3M
31 Mar 2025–-$17.7M
31 Dec 2024$0-$16.6M
30 Sep 2024$0-$21.7M
30 Jun 2024$80.0M$55.4M
31 Mar 2024$0-$26.9M
31 Dec 2023$871K-$24.8M
30 Sep 2023$759K-$24.0M
30 Jun 2023$880K-$23.8M
31 Mar 2023$295K-$24.8M
31 Dec 2022$685K-$26.1M
30 Sep 2022$1.2M-$23.7M
30 Jun 2022$1.9M-$34.1M
31 Mar 2022$2.6M-$25.9M
31 Dec 2021$5.1M-$23.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$76.3M -$71.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.04 -$1.14
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -30.5% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $116.4M $47.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$116.4M (net cash) -$47.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $3.95
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.93 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Fulcrum TherapeuticsFULC (this company) $281.8Mloss–––
Greenwich LifeSciencesGLSI $282.6Mloss–––
Relmada TherapeuticsRLMD $279.5Mloss–––
Benitec BiopharmaBNTC $285.9Mloss–––
EvommuneEVMN $291.1Mloss–––
Galectin TherapeuticsGALT $271.4Mloss–––

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-2.6%

149 13F filers vs 153

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

78.4M shares held by 13F filers (30 Sep 2026) of 76.4M outstanding (8 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

8.4%

6.4M shares sold short (30 Oct 2026) of 76.4M outstanding (8 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

4.8

6.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-4.7%

6.8M shares sold short in the report before, 6.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

68%

68% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 44%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$150K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

11

11 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

11×

11 articles in the last 7 days; its usual week has 1.

Price $3.69 on 20 Nov 2026, -67% over 12 months (12-month range $3.14 to $14.60)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $57.3M in the last 12 months (the 12 months before: -$168K).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 0 published in the last 12 months.
Revenue per quarter. Revenue $0 in the latest quarter.
Capital spending per quarter. Capital spending $108K in the latest quarter, +66% on a year earlier.
Institutional holders (13F filers). 149 13F filers reported holding it in the latest 13F quarter, +22% on a year earlier.
Lobbying spend. Lobbying spend: $150K published in the last 12 months, +25% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
17 Aug 20268-K and other filingsDirector or officer change
10 Aug 20268-K and other filingsDirector or officer change
20 Jul 2026Lobbying filinglobbying engagement terminated (THE MCMANUS GROUP)
11 Jun 20268-K and other filingsDirector or officer change
4 Jun 20268-K and other filingsRestructuring costs announced
12 May 2026Sharp changeShort interest spike: short interest spike, 8.0M vs usual 3.8M (2026-04-30); 2.3x the same period a year earlier
28 Apr 2026Sharp changeShort interest spike: short interest spike, 7.6M vs usual 3.8M (2026-04-15); 2.1x the same period a year earlier
27 Apr 20268-K and other filingsDirector or officer change
27 Apr 20268-K and other filingsA major agreement ended
27 Apr 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Apr 2026Sharp changeShort interest spike: short interest spike, 7.0M vs usual 3.7M (2026-03-31); 1.9x the same period a year earlier
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 54 vs usual 23 (2025-12-31); 2.8x the same period a year earlier
4 Mar 20258-K and other filingsA major agreement ended
21 Jan 2025Lobbying filinglobbying engagement terminated (THE KPM GROUP DC LLC)
17 Jan 2025Lobbying filingnew lobbying registration (THE MCMANUS GROUP)
23 Dec 20248-K and other filingsA major agreement ended
12 Nov 20248-K and other filingsDirector or officer change
12 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Oct 2024Sharp changeShort interest spike: short interest spike, 11.4M vs usual 3.7M (2024-09-13); 3.0x the same period a year earlier
24 Sep 20248-K and other filingsRestructuring costs announced
17 Sep 2024Sharp changeShort interest spike: short interest spike, 8.1M vs usual 3.7M (2024-08-30); 2.3x the same period a year earlier
27 Aug 2024Sharp changeShort interest spike: short interest spike, 8.2M vs usual 3.6M (2024-08-15); 3.0x the same period a year earlier
13 Aug 2024Sharp changeShort interest spike: short interest spike, 7.7M vs usual 3.6M (2024-07-31); 2.2x the same period a year earlier
6 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 80.0M vs usual 815K (2024-06-30); 90.9x the same period a year earlier
30 Jul 2024Sharp changeShort interest spike: short interest spike, 7.3M vs usual 3.5M (2024-07-15); 2.1x the same period a year earlier
19 Jul 2024Sharp changeLobbying on a new issue: lobbying on a new issue: PHA (2024-06-30)
17 Jun 20248-K and other filingsDirector or officer change
17 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
2 Oct 20238-K and other filingsDirector or officer change
3 Aug 20238-K and other filingsDirector or officer change
15 May 20238-K and other filingsDirector or officer change
2 May 2023Sharp changeShort interest spike: short interest spike, 5.1M vs usual 3.5M (2023-04-14); 1.9x the same period a year earlier
18 Apr 2023Sharp changeShort interest spike: short interest spike, 4.9M vs usual 3.5M (2023-03-31); 1.8x the same period a year earlier
5 Apr 20238-K and other filingsDirector or officer change
5 Apr 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Jan 20238-K and other filingsDirector or officer change
19 Oct 20228-K and other filingsDirector or officer change
8 Sep 2022Lobbying filingnew lobbying registration (THE KPM GROUP DC LLC)
8 Sep 2022Sharp changeFirst lobbying registration: first lobbying registration: FULCRUM THERAPEUTICS, INC.: new lobbying registration (THE KPM GROUP DC LLC)
11 Aug 20228-K and other filingsDirector or officer change
11 Aug 20228-K and other filingsRestructuring costs announced
11 Jul 20228-K and other filingsDirector or officer change
11 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jun 20228-K and other filingsA major agreement ended
10 Mar 20228-K and other filingsDirector or officer change
1 Mar 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 813K (2022-02-15); 3.6x the same period a year earlier
15 Feb 2022Sharp changeMany funds opening a new position: many funds opening a new position, 26 vs usual 10.50 (2021-12-31); 2.2x the same period a year earlier
15 Feb 2022Sharp changeShort interest spike: short interest spike, 2.1M vs usual 813K (2022-01-31); 3.0x the same period a year earlier
1 Feb 2022Sharp changeShort interest spike: short interest spike, 1.8M vs usual 813K (2022-01-14); 2.0x the same period a year earlier
10 Jan 20228-K and other filingsDirector or officer change
4 Jan 20228-K and other filingsDirector or officer change
28 Dec 2021Sharp changeShort interest spike: short interest spike, 1.7M vs usual 813K (2021-12-15); 1.9x the same period a year earlier
14 Dec 2021Sharp changeShort interest spike: short interest spike, 2.1M vs usual 813K (2021-11-30); 2.2x the same period a year earlier
30 Nov 2021Sharp changeShort interest spike: short interest spike, 3.0M vs usual 813K (2021-11-15); 2.9x the same period a year earlier
Insider net buying (open market)
Month from 1 Apr 2022: -$2.4M published
Month from 1 Jun 2022: -$1.1M published
Month from 1 Dec 2022: $13.7M published
Month from 1 Jan 2023: $26.2M published
Month from 1 May 2023: -$695 published
Month from 1 Mar 2024: $435K published
Month from 1 May 2024: -$2K published
Month from 1 May 2025: -$3K published
Month from 1 Nov 2025: -$165K published
Month from 1 Dec 2025: -$58.4M published
Month from 1 Jan 2026: -$178K published
Month from 1 Feb 2026: -$161K published
Month from 1 Jul 2026: $1.4M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 2 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $5.1M, +20% on a year earlier; public on 4 Mar 2022
Quarter ended 31 Mar 2022: $2.6M, -46% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $1.9M, -57% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $1.2M, -76% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $685K, -86% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $295K, -89% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $880K, -53% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $759K, -36% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $871K, +27% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 14 May 2024
Quarter ended 30 Jun 2024: $80.0M, +8991% on a year earlier; public on 1 Aug 2024
Quarter ended 30 Sep 2024: $0, -100% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $0, -100% on a year earlier; public on 26 Feb 2025
Quarter ended 30 Jun 2025: $0, -100% on a year earlier; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $0; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $0; public on 25 Feb 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $519K, +10% on a year earlier; public on 4 Mar 2022
Quarter ended 31 Mar 2022: $246K, -6.1% on a year earlier; public on 10 May 2022
Quarter ended 30 Jun 2022: $1.3M, +133% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $283K, -23% on a year earlier; public on 9 Nov 2022
Quarter ended 31 Dec 2022: $116K, -78% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $171K, -30% on a year earlier; public on 16 May 2023
Quarter ended 30 Jun 2023: $195K, -85% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $65K, -77% on a year earlier; public on 8 Nov 2023
Quarter ended 31 Dec 2023: $77K, -34% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $28K, -84% on a year earlier; public on 14 May 2024
Quarter ended 30 Sep 2024: $19K, -71% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Mar 2025: $0, -100% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $65K; public on 30 Jul 2025
Quarter ended 30 Sep 2025: $90K, +374% on a year earlier; public on 30 Oct 2025
Quarter ended 31 Dec 2025: $159K; public on 25 Feb 2026
Quarter ended 31 Mar 2026: $8K; public on 28 Apr 2026
Quarter ended 30 Jun 2026: $108K, +66% on a year earlier; public on 31 Jul 2026
Institutional holders (13F filers)
31 Dec 2021 report: 100; public on 14 Feb 2022
31 Mar 2022 report: 102; public on 16 May 2022
30 Jun 2022 report: 96; public on 15 Aug 2022
30 Sep 2022 report: 101; public on 14 Nov 2022
31 Dec 2022 report: 106; public on 14 Feb 2023
31 Mar 2023 report: 112; public on 15 May 2023
30 Jun 2023 report: 85; public on 14 Aug 2023
30 Sep 2023 report: 77; public on 14 Nov 2023
31 Dec 2023 report: 99; public on 14 Feb 2024
31 Mar 2024 report: 124; public on 15 May 2024
30 Jun 2024 report: 116; public on 14 Aug 2024
30 Sep 2024 report: 125; public on 14 Nov 2024
31 Dec 2024 report: 118; public on 14 Feb 2025
31 Mar 2025 report: 113; public on 15 May 2025
30 Jun 2025 report: 119; public on 14 Aug 2025
30 Sep 2025 report: 122; public on 14 Nov 2025
31 Dec 2025 report: 167; public on 17 Feb 2026
31 Mar 2026 report: 162; public on 15 May 2026
30 Jun 2026 report: 153; public on 14 Aug 2026
30 Sep 2026 report: 149; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Oct 2022: $20K published
Quarter from 1 Jan 2023: $30K published
Quarter from 1 Apr 2023: $30K published
Quarter from 1 Jul 2023: $30K published
Quarter from 1 Oct 2023: $30K published
Quarter from 1 Jan 2024: $30K published
Quarter from 1 Apr 2024: $30K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $60K published
Quarter from 1 Apr 2025: $40K published
Quarter from 1 Jul 2025: $40K published
Quarter from 1 Oct 2025: $40K published
Quarter from 1 Jan 2026: $40K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $60K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market buying (USD, Form 4) at $595K (20 Jul 2026), higher than 88% of its own history.
  • Insider net buying (open market): Insiders sold a net $57.3M in the last 12 months (the 12 months before: -$168K).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 0 published in the last 12 months.
  • Revenue per quarter: Revenue $0 in the latest quarter.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 68 insider trades

No trades in the last 90 days; the latest was filed 20 Jul 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Jul 2026Kevin Tang and 1 other10% ownerBuy167,616$3.55$595KForm 4
15 Jul 2026Tang Capital Management LLC and 1 other10% ownerBuy249,946$3.57$891KForm 4
30 Jun 2026Alan EzekowitzDirectorSell18,000$3.65$66KForm 4
4 Feb 2026Robert J GouldDirectorSell15,000$10.72$161KForm 4
6 Jan 2026Robert J GouldDirectorSell15,000$11.87$178KForm 4
17 Dec 2025Curtis Gale OltmansChief Legal OfficerSell3,452$12.92$45KForm 4
10 Dec 2025RA Capital Healthcare Fund LP and 3 others10% ownerSell4,175,139$13.98$58.4MForm 4
21 Nov 2025Robert J GouldDirectorSell15,000$11.03$165KForm 4

149 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 24 opened a position, 27 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
BlackRock, Inc.11.6M15.2%$43.0M+2.8M+32%
Tang Capital Management LLC7.1M9.27%$26.2M+560K+8.6%
EcoR1 Capital, LLC6.8M8.91%$25.2M+254K+3.9%
ADAR1 Capital Management, LLC6.6M8.70%$24.6M+5.1M+325%
Nantahala Capital Management, LLC6.6M8.61%$24.3M-4.4M-40%
D. E. Shaw & Co., Inc.3.7M4.86%$13.7M+664K+22%
Vanguard Capital Management LLC2.9M3.75%$10.6M+168K+6.2%
Two Sigma Investments, LP2.6M3.39%$9.6M+1.8M+219%
Renaissance Technologies LLC2.2M2.91%$8.2M+572K+35%
Marshall Wace, LLP1.9M2.48%$7.0M+535K+39%

Company events

All 49 company events

In 12 months: 4 director or officer changes, 2 major agreements, 1 agreement ended, 1 restructuring. Results releases and routine reports are left out.

FiledWhat happenedSource
17 Aug 2026Director or officer change; Signed a major agreementSame filing: sold shares privately, change of control8-K
10 Aug 2026Director or officer change8-K
11 Jun 2026Director or officer change8-K
4 Jun 2026Restructuring costs announced8-K
27 Apr 2026Director or officer change; A major agreement ended8-K
10 Dec 2025Signed a major agreement8-K
4 Mar 2025A major agreement ended8-K
23 Dec 2024A major agreement ended8-K

Reported lobbying spend: $60K in Q2 2026, $50K in Q1 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
30 Jun 2026EndedThe Mcmanus Groupfor Fulcrum TherapeuticsEducation and advocacy regarding sickle cell disease, including H.R. 1796/S. 735- Sickle Cell Disease and Other Heritable Blood Disorders, Research, Surveillance, Prevention, and Treatment Act of 2025.Health issuesFiling
1 Jan 2025NewThe Mcmanus Groupfor Fulcrum TherapeuticsSickle Cell disease education Orphan Drug Tax Credit Priority review vouchersHealth issuesFiling
31 Dec 2024EndedThe KPM Group DC LLCfor Fulcrum Therapeutics, Inc.Not statedFiling
1 Sep 2022NewThe KPM Group DC LLCfor Fulcrum Therapeutics, Inc.Any legislation regarding rare disease treatmentHealth issuesFiling

The 5 newest of 105 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

30 Jul 2024confirmed

Confirmed across sources Filings + Financials and Lobbying and Short interest and volume

Fulcrum Therapeutics (FULC): lobbying on a new issue; it also reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year; and it had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year. Three unrelated kinds of activity within 74 days.

  • Lobbying: Lobbying on a new issue, became public on 19 Jul 2024
  • Short interest and volume: Short interest spike, became public on 25 Jul 2024
  • Financials: Quarterly revenue change, became public on 6 Aug 2024
  • Short interest and volume: Short interest spike, became public on 10 Aug 2024
  • Short interest and volume: Short interest spike, became public on 27 Aug 2024
  • Short interest and volume: Short interest spike, became public on 12 Sep 2024
  • Short interest and volume: Short interest spike, became public on 25 Sep 2024
2022-06-30: $1.9M2022-09-30: $1.2M2022-12-31: $685K2023-03-31: $295K2023-06-30: $880K2023-09-30: $759K2023-12-31: $871K2024-03-31: $02024-06-30: $80.0M
The quarter ended 30 Jun 2024 against the 8 quarters before it. this quarterearliernormal: $815K
See the evidence (7 changes)

Lobbying: Lobbying on a new issue became public on 19 Jul 2024

Fulcrum Therapeutics lobbying on a new issue.

New
['PHA']
Rule
only points whose every posting (and value revision) is at or before as_of
Field
issue_codes
Metric
lobbying.filings_count
Point id
6409906

Short interest and volume: Short interest spike became public on 25 Jul 2024

Fulcrum Therapeutics had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.

This period
7.3M (the 15 Jul 2024 report)
Normal report (median of 24 earlier)
3.5M
Typical spread (median absolute deviation)
360K
How far from its usual level
+7.0
Same report last year
3.5M
History used
1,811 days
2023-07-14: 3.5M2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M
the 15 Jul 2024 report24 earlier reportsnormal: 3.5M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Financials: Quarterly revenue change became public on 6 Aug 2024

Fulcrum Therapeutics reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.

This period
$80.0M (the quarter ended 30 Jun 2024)
Normal quarter (median of 8 earlier)
$815K
Typical spread (median absolute deviation)
$249K
How far from its usual level
+79.2
Same quarter last year
$880K
History used
1,552 days
2022-06-30: $1.9M2022-09-30: $1.2M2022-12-31: $685K2023-03-31: $295K2023-06-30: $880K2023-09-30: $759K2023-12-31: $871K2024-03-31: $02024-06-30: $80.0M
the quarter ended 30 Jun 20248 earlier quartersnormal: $815K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

Check it at the source: SEC EDGAR quarterly reports.

Short interest and volume: Short interest spike became public on 10 Aug 2024

Fulcrum Therapeutics had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.

This period
7.7M (the 31 Jul 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
379K
How far from its usual level
+7.3
Same report last year
3.5M
History used
1,827 days
2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M
the 31 Jul 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Aug 2024

Fulcrum Therapeutics had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.

This period
8.2M (the 15 Aug 2024 report)
Normal report (median of 24 earlier)
3.6M
Typical spread (median absolute deviation)
411K
How far from its usual level
+7.4
Same report last year
2.7M
History used
1,842 days
2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M
the 15 Aug 2024 report24 earlier reportsnormal: 3.6M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 12 Sep 2024

Fulcrum Therapeutics had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.

This period
8.1M (the 30 Aug 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
365K
How far from its usual level
+8.1
Same report last year
3.6M
History used
1,857 days
2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M
the 30 Aug 2024 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Sep 2024

Fulcrum Therapeutics had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.

This period
11.4M (the 13 Sep 2024 report)
Normal report (median of 24 earlier)
3.7M
Typical spread (median absolute deviation)
448K
How far from its usual level
+11.5
Same report last year
3.7M
History used
1,871 days
2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M2024-09-13: 11.4M
the 13 Sep 2024 report24 earlier reportsnormal: 3.7M

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

15 Feb 2022confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Fulcrum Therapeutics (FULC): saw 26 13F filers open a new position in the quarter ended 31 Dec 2021, 2.2× the same quarter last year, while it had 2.6M shares sold short in the 15 Feb 2022 report, 3.6× the same report last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 27 Jan 2022
  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2022
  • Short interest and volume: Short interest spike, became public on 10 Feb 2022
  • Short interest and volume: Short interest spike, became public on 26 Feb 2022
2019-12-31: 32020-03-31: 112020-06-30: 182020-09-30: 72020-12-31: 122021-03-31: 102021-06-30: 102021-09-30: 382021-12-31: 26
The quarter ended 31 Dec 2021 against the 8 quarters before it. this quarterearliernormal: 10.5
See the evidence (4 changes)

Short interest and volume: Short interest spike became public on 27 Jan 2022

Fulcrum Therapeutics had 1.8M shares sold short in the 14 Jan 2022 report, 2.0× the same report last year.

This period
1.8M (the 14 Jan 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
128K
How far from its usual level
+5.1
Same report last year
905K
History used
898 days
2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M2021-11-30: 2.1M2021-12-15: 1.7M2022-01-14: 1.8M
the 14 Jan 2022 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 14 Feb 2022

Fulcrum Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2021, 2.2× the same quarter last year.

This period
26 (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+4.2
Same quarter last year
12
History used
823 days
2019-12-31: 32020-03-31: 112020-06-30: 182020-09-30: 72020-12-31: 122021-03-31: 102021-06-30: 102021-09-30: 382021-12-31: 26
the quarter ended 31 Dec 20218 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Feb 2022

Fulcrum Therapeutics had 2.1M shares sold short in the 31 Jan 2022 report, 3.0× the same report last year.

This period
2.1M (the 31 Jan 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
128K
How far from its usual level
+6.8
Same report last year
708K
History used
915 days
2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M2021-11-30: 2.1M2021-12-15: 1.7M2022-01-14: 1.8M2022-01-31: 2.1M
the 31 Jan 2022 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 26 Feb 2022

Fulcrum Therapeutics had 2.6M shares sold short in the 15 Feb 2022 report, 3.6× the same report last year.

This period
2.6M (the 15 Feb 2022 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
143K
How far from its usual level
+8.7
Same report last year
724K
History used
930 days
2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M2021-11-30: 2.1M2021-12-15: 1.7M2022-01-14: 1.8M2022-01-31: 2.1M2022-02-15: 2.6M
the 15 Feb 2022 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

16 Nov 2021confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Fulcrum Therapeutics (FULC): saw 38 13F filers open a new position in the quarter ended 30 Sep 2021, 5.4× the same quarter last year, while it had 3.0M shares sold short in the 15 Nov 2021 report, 2.9× the same report last year. Two unrelated kinds of activity within 70 days.

  • Short interest and volume: Short interest spike, became public on 13 Oct 2021
  • Short interest and volume: Short interest spike, became public on 27 Oct 2021
  • Institutional holdings: Many funds opening a new position, became public on 15 Nov 2021
  • Short interest and volume: Short interest spike, became public on 10 Nov 2021
  • Short interest and volume: Short interest spike, became public on 25 Nov 2021
  • Short interest and volume: Short interest spike, became public on 10 Dec 2021
  • Short interest and volume: Short interest spike, became public on 28 Dec 2021
2019-09-30: 352019-12-31: 32020-03-31: 112020-06-30: 182020-09-30: 72020-12-31: 122021-03-31: 102021-06-30: 102021-09-30: 38
The quarter ended 30 Sep 2021 against the 8 quarters before it. this quarterearliernormal: 10.5
See the evidence (7 changes)

Short interest and volume: Short interest spike became public on 13 Oct 2021

Fulcrum Therapeutics had 2.1M shares sold short in the 30 Sep 2021 report, 1.8× the same report last year.

This period
2.1M (the 30 Sep 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.1M
History used
792 days
2020-09-30: 1.1M2020-10-15: 1.2M2020-10-30: 1.3M2020-11-13: 1.0M2020-11-30: 931K2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M
the 30 Sep 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 27 Oct 2021

Fulcrum Therapeutics had 2.1M shares sold short in the 15 Oct 2021 report, 1.7× the same report last year.

This period
2.1M (the 15 Oct 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.2M
History used
807 days
2020-10-15: 1.2M2020-10-30: 1.3M2020-11-13: 1.0M2020-11-30: 931K2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M
the 15 Oct 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 15 Nov 2021

Fulcrum Therapeutics saw 38 13F filers open a new position in the quarter ended 30 Sep 2021, 5.4× the same quarter last year.

This period
38 (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
10.5
Typical spread (median absolute deviation)
2.5
How far from its usual level
+7.4
Same quarter last year
7
History used
731 days
2019-09-30: 352019-12-31: 32020-03-31: 112020-06-30: 182020-09-30: 72020-12-31: 122021-03-31: 102021-06-30: 102021-09-30: 38
the quarter ended 30 Sep 20218 earlier quartersnormal: 10.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 10 Nov 2021

Fulcrum Therapeutics had 2.1M shares sold short in the 29 Oct 2021 report, 1.6× the same report last year.

This period
2.1M (the 29 Oct 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.2
Same report last year
1.3M
History used
821 days
2020-10-30: 1.3M2020-11-13: 1.0M2020-11-30: 931K2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M
the 29 Oct 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Nov 2021

Fulcrum Therapeutics had 3.0M shares sold short in the 15 Nov 2021 report, 2.9× the same report last year.

This period
3.0M (the 15 Nov 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+12.7
Same report last year
1.0M
History used
838 days
2020-11-13: 1.0M2020-11-30: 931K2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M
the 15 Nov 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2021

Fulcrum Therapeutics had 2.1M shares sold short in the 30 Nov 2021 report, 2.2× the same report last year.

This period
2.1M (the 30 Nov 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
118K
How far from its usual level
+7.3
Same report last year
931K
History used
853 days
2020-11-30: 931K2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M2021-11-30: 2.1M
the 30 Nov 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 28 Dec 2021

Fulcrum Therapeutics had 1.7M shares sold short in the 15 Dec 2021 report, 1.9× the same report last year.

This period
1.7M (the 15 Dec 2021 report)
Normal report (median of 24 earlier)
813K
Typical spread (median absolute deviation)
120K
How far from its usual level
+5.0
Same report last year
884K
History used
868 days
2020-12-15: 884K2020-12-31: 1.0M2021-01-15: 905K2021-01-29: 708K2021-02-12: 724K2021-02-26: 691K2021-03-15: 705K2021-03-31: 768K2021-04-15: 771K2021-04-30: 743K2021-05-14: 717K2021-05-28: 679K2021-06-15: 662K2021-06-30: 855K2021-07-15: 750K2021-07-30: 695K2021-08-13: 2.5M2021-08-31: 1.6M2021-09-15: 1.7M2021-09-30: 2.1M2021-10-15: 2.1M2021-10-29: 2.1M2021-11-15: 3.0M2021-11-30: 2.1M2021-12-15: 1.7M
the 15 Dec 2021 report24 earlier reportsnormal: 813K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 17 Aug 2026Filings record

    Director or officer change

  2. 10 Aug 2026Filings record

    Director or officer change

  3. 21 Jul 2026Insiders record

    TANG KEVIN (ten percent owner) and 1 other(s) bought 167,616 shares of FULC ($594,675) (dated 20 Jul 2026)

  4. 20 Jul 2026Lobbying record

    FULCRUM THERAPEUTICS: lobbying engagement terminated (THE MCMANUS GROUP) (dated 30 Jun 2026)

  5. 16 Jul 2026Insiders record

    TANG CAPITAL MANAGEMENT LLC (ten percent owner) and 1 other(s) bought 249,946 shares of FULC ($891,067) (dated 15 Jul 2026)

  6. 11 Jun 2026Filings record

    Director or officer change

  7. 4 Jun 2026Filings record

    Restructuring costs announced

  8. 12 May 2026Short interest and volume change

    had 8.0M shares sold short in the 30 Apr 2026 report, 2.3× the same report last year.

    Same report last year: 3.4M; its normal report is 3.8M.

    See the evidence
    This period
    8.0M (the 30 Apr 2026 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    530K
    How far from its usual level
    +5.3
    Same report last year
    3.4M
    History used
    2,465 days
    2025-04-30: 3.4M2025-05-15: 4.9M2025-05-30: 5.7M2025-06-13: 5.8M2025-06-30: 5.6M2025-07-15: 4.9M2025-07-31: 5.0M2025-08-15: 5.8M2025-08-29: 3.7M2025-09-15: 3.7M2025-09-30: 3.3M2025-10-15: 3.6M2025-10-31: 3.5M2025-11-14: 3.6M2025-11-28: 3.8M2025-12-15: 3.0M2025-12-31: 3.3M2026-01-15: 3.6M2026-01-30: 3.9M2026-02-13: 3.5M2026-02-27: 4.2M2026-03-13: 4.9M2026-03-31: 7.0M2026-04-15: 7.6M2026-04-30: 8.0M
    the 30 Apr 2026 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  9. 27 Apr 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 27 Apr 2026Filings record

    Director or officer change

  11. 27 Apr 2026Filings record

    A major agreement ended

  12. 25 Apr 2026Short interest and volume change

    had 7.6M shares sold short in the 15 Apr 2026 report, 2.1× the same report last year.

    Same report last year: 3.6M; its normal report is 3.8M.

    See the evidence
    This period
    7.6M (the 15 Apr 2026 report)
    Normal report (median of 24 earlier)
    3.8M
    Typical spread (median absolute deviation)
    431K
    How far from its usual level
    +5.9
    Same report last year
    3.6M
    History used
    2,450 days
    2025-04-15: 3.6M2025-04-30: 3.4M2025-05-15: 4.9M2025-05-30: 5.7M2025-06-13: 5.8M2025-06-30: 5.6M2025-07-15: 4.9M2025-07-31: 5.0M2025-08-15: 5.8M2025-08-29: 3.7M2025-09-15: 3.7M2025-09-30: 3.3M2025-10-15: 3.6M2025-10-31: 3.5M2025-11-14: 3.6M2025-11-28: 3.8M2025-12-15: 3.0M2025-12-31: 3.3M2026-01-15: 3.6M2026-01-30: 3.9M2026-02-13: 3.5M2026-02-27: 4.2M2026-03-13: 4.9M2026-03-31: 7.0M2026-04-15: 7.6M
    the 15 Apr 2026 report24 earlier reportsnormal: 3.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  13. 11 Apr 2026Short interest and volume change

    had 7.0M shares sold short in the 31 Mar 2026 report, 1.9× the same report last year.

    Same report last year: 3.7M; its normal report is 3.7M.

    See the evidence
    This period
    7.0M (the 31 Mar 2026 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    351K
    How far from its usual level
    +6.2
    Same report last year
    3.7M
    History used
    2,435 days
    2025-03-31: 3.7M2025-04-15: 3.6M2025-04-30: 3.4M2025-05-15: 4.9M2025-05-30: 5.7M2025-06-13: 5.8M2025-06-30: 5.6M2025-07-15: 4.9M2025-07-31: 5.0M2025-08-15: 5.8M2025-08-29: 3.7M2025-09-15: 3.7M2025-09-30: 3.3M2025-10-15: 3.6M2025-10-31: 3.5M2025-11-14: 3.6M2025-11-28: 3.8M2025-12-15: 3.0M2025-12-31: 3.3M2026-01-15: 3.6M2026-01-30: 3.9M2026-02-13: 3.5M2026-02-27: 4.2M2026-03-13: 4.9M2026-03-31: 7.0M
    the 31 Mar 2026 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  14. 17 Feb 2026Institutional holdings change

    saw 54 13F filers open a new position in the quarter ended 31 Dec 2025, 2.8× the same quarter last year.

    Same quarter last year: 19; its normal quarter is 23.

    See the evidence
    This period
    54 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    23
    Typical spread (median absolute deviation)
    4
    How far from its usual level
    +5.2
    Same quarter last year
    19
    History used
    2,284 days
    2023-12-31: 222024-03-31: 342024-06-30: 272024-09-30: 382024-12-31: 192025-03-31: 162025-06-30: 232025-09-30: 232025-12-31: 54
    the quarter ended 31 Dec 20258 earlier quartersnormal: 23

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  15. 4 Mar 2025Filings record

    A major agreement ended

  16. 21 Jan 2025Lobbying record

    FULCRUM THERAPEUTICS, INC.: lobbying engagement terminated (THE KPM GROUP DC LLC) (dated 31 Dec 2024)

  17. 17 Jan 2025Lobbying record

    FULCRUM THERAPEUTICS: new lobbying registration (THE MCMANUS GROUP) (dated 1 Jan 2025)

  18. 23 Dec 2024Filings record

    A major agreement ended

  19. 12 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  20. 12 Nov 2024Filings record

    Director or officer change

  21. 25 Sep 2024Short interest and volume change

    had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.

    Same report last year: 3.7M; its normal report is 3.7M.

    See the evidence
    This period
    11.4M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    448K
    How far from its usual level
    +11.5
    Same report last year
    3.7M
    History used
    1,871 days
    2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M2024-09-13: 11.4M
    the 13 Sep 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  22. 24 Sep 2024Filings record

    Restructuring costs announced

  23. 12 Sep 2024Short interest and volume change

    had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.

    Same report last year: 3.6M; its normal report is 3.7M.

    See the evidence
    This period
    8.1M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +8.1
    Same report last year
    3.6M
    History used
    1,857 days
    2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M
    the 30 Aug 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 27 Aug 2024Short interest and volume change

    had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.

    Same report last year: 2.7M; its normal report is 3.6M.

    See the evidence
    This period
    8.2M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    411K
    How far from its usual level
    +7.4
    Same report last year
    2.7M
    History used
    1,842 days
    2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M
    the 15 Aug 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 10 Aug 2024Short interest and volume change

    had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.

    Same report last year: 3.5M; its normal report is 3.6M.

    See the evidence
    This period
    7.7M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    379K
    How far from its usual level
    +7.3
    Same report last year
    3.5M
    History used
    1,827 days
    2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M
    the 31 Jul 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 6 Aug 2024Financials change

    reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.

    Same quarter last year: $880K; its normal quarter is $815K.

    See the evidence
    This period
    $80.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $815K
    Typical spread (median absolute deviation)
    $249K
    How far from its usual level
    +79.2
    Same quarter last year
    $880K
    History used
    1,552 days
    2022-06-30: $1.9M2022-09-30: $1.2M2022-12-31: $685K2023-03-31: $295K2023-06-30: $880K2023-09-30: $759K2023-12-31: $871K2024-03-31: $02024-06-30: $80.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $815K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  27. 30 Jul 2024several at once

    lobbying on a new issue; it also reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year; and it had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year. Three unrelated kinds of activity within 74 days.

    See the evidence (7 changes)

    Lobbying: Lobbying on a new issue became public on 19 Jul 2024

    Fulcrum Therapeutics lobbying on a new issue.

    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6409906

    Short interest and volume: Short interest spike became public on 25 Jul 2024

    Fulcrum Therapeutics had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.

    This period
    7.3M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    360K
    How far from its usual level
    +7.0
    Same report last year
    3.5M
    History used
    1,811 days
    2023-07-14: 3.5M2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Financials: Quarterly revenue change became public on 6 Aug 2024

    Fulcrum Therapeutics reported revenue of $80.0M for the quarter ended 30 Jun 2024, 91× the same quarter last year.

    This period
    $80.0M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $815K
    Typical spread (median absolute deviation)
    $249K
    How far from its usual level
    +79.2
    Same quarter last year
    $880K
    History used
    1,552 days
    2022-06-30: $1.9M2022-09-30: $1.2M2022-12-31: $685K2023-03-31: $295K2023-06-30: $880K2023-09-30: $759K2023-12-31: $871K2024-03-31: $02024-06-30: $80.0M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $815K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Short interest and volume: Short interest spike became public on 10 Aug 2024

    Fulcrum Therapeutics had 7.7M shares sold short in the 31 Jul 2024 report, 2.2× the same report last year.

    This period
    7.7M (the 31 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    379K
    How far from its usual level
    +7.3
    Same report last year
    3.5M
    History used
    1,827 days
    2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M
    the 31 Jul 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 27 Aug 2024

    Fulcrum Therapeutics had 8.2M shares sold short in the 15 Aug 2024 report, 3.0× the same report last year.

    This period
    8.2M (the 15 Aug 2024 report)
    Normal report (median of 24 earlier)
    3.6M
    Typical spread (median absolute deviation)
    411K
    How far from its usual level
    +7.4
    Same report last year
    2.7M
    History used
    1,842 days
    2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M
    the 15 Aug 2024 report24 earlier reportsnormal: 3.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 12 Sep 2024

    Fulcrum Therapeutics had 8.1M shares sold short in the 30 Aug 2024 report, 2.3× the same report last year.

    This period
    8.1M (the 30 Aug 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    365K
    How far from its usual level
    +8.1
    Same report last year
    3.6M
    History used
    1,857 days
    2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M
    the 30 Aug 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Sep 2024

    Fulcrum Therapeutics had 11.4M shares sold short in the 13 Sep 2024 report, 3.0× the same report last year.

    This period
    11.4M (the 13 Sep 2024 report)
    Normal report (median of 24 earlier)
    3.7M
    Typical spread (median absolute deviation)
    448K
    How far from its usual level
    +11.5
    Same report last year
    3.7M
    History used
    1,871 days
    2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M2024-07-31: 7.7M2024-08-15: 8.2M2024-08-30: 8.1M2024-09-13: 11.4M
    the 13 Sep 2024 report24 earlier reportsnormal: 3.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  28. 25 Jul 2024Short interest and volume change

    had 7.3M shares sold short in the 15 Jul 2024 report, 2.1× the same report last year.

    Same report last year: 3.5M; its normal report is 3.5M.

    See the evidence
    This period
    7.3M (the 15 Jul 2024 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    360K
    How far from its usual level
    +7.0
    Same report last year
    3.5M
    History used
    1,811 days
    2023-07-14: 3.5M2023-07-31: 3.5M2023-08-15: 2.7M2023-08-31: 3.6M2023-09-15: 3.7M2023-09-29: 4.0M2023-10-13: 3.9M2023-10-31: 4.0M2023-11-15: 3.7M2023-11-30: 4.1M2023-12-15: 3.3M2023-12-29: 3.7M2024-01-12: 4.0M2024-01-31: 3.4M2024-02-15: 3.2M2024-02-29: 3.2M2024-03-15: 2.4M2024-03-28: 2.3M2024-04-15: 2.5M2024-04-30: 3.0M2024-05-15: 3.1M2024-05-31: 3.6M2024-06-14: 3.9M2024-06-28: 5.3M2024-07-15: 7.3M
    the 15 Jul 2024 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 19 Jul 2024Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['PHA']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    6409906
  30. 17 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  31. 17 Jun 2024Filings record

    Director or officer change

  32. 6 Mar 2024Insiders record

    Sapir Alex (See Remarks) bought 43,360 shares of FULC ($492,136) (dated 5 Mar 2024)

  33. 2 Oct 2023Filings record

    Director or officer change

  34. 3 Aug 2023Filings record

    Director or officer change

  35. 15 May 2023Filings record

    Director or officer change

  36. 26 Apr 2023Short interest and volume change

    had 5.1M shares sold short in the 14 Apr 2023 report, 1.9× the same report last year.

    Same report last year: 2.7M; its normal report is 3.5M.

    See the evidence
    This period
    5.1M (the 14 Apr 2023 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    207K
    How far from its usual level
    +4.5
    Same report last year
    2.7M
    History used
    1,353 days
    2022-04-14: 2.7M2022-04-29: 4.4M2022-05-13: 3.4M2022-05-31: 3.7M2022-06-15: 3.5M2022-06-30: 3.7M2022-07-15: 3.8M2022-07-29: 3.5M2022-08-15: 3.2M2022-08-31: 3.4M2022-09-15: 3.9M2022-09-30: 3.6M2022-10-14: 3.5M2022-10-31: 3.5M2022-11-15: 3.4M2022-11-30: 3.3M2022-12-15: 3.0M2022-12-30: 3.6M2023-01-13: 3.3M2023-01-31: 3.5M2023-02-15: 3.8M2023-02-28: 4.1M2023-03-15: 3.9M2023-03-31: 4.9M2023-04-14: 5.1M
    the 14 Apr 2023 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 13 Apr 2023Short interest and volume change

    had 4.9M shares sold short in the 31 Mar 2023 report, 1.8× the same report last year.

    Same report last year: 2.7M; its normal report is 3.5M.

    See the evidence
    This period
    4.9M (the 31 Mar 2023 report)
    Normal report (median of 24 earlier)
    3.5M
    Typical spread (median absolute deviation)
    217K
    How far from its usual level
    +4.1
    Same report last year
    2.7M
    History used
    1,339 days
    2022-03-31: 2.7M2022-04-14: 2.7M2022-04-29: 4.4M2022-05-13: 3.4M2022-05-31: 3.7M2022-06-15: 3.5M2022-06-30: 3.7M2022-07-15: 3.8M2022-07-29: 3.5M2022-08-15: 3.2M2022-08-31: 3.4M2022-09-15: 3.9M2022-09-30: 3.6M2022-10-14: 3.5M2022-10-31: 3.5M2022-11-15: 3.4M2022-11-30: 3.3M2022-12-15: 3.0M2022-12-30: 3.6M2023-01-13: 3.3M2023-01-31: 3.5M2023-02-15: 3.8M2023-02-28: 4.1M2023-03-15: 3.9M2023-03-31: 4.9M
    the 31 Mar 2023 report24 earlier reportsnormal: 3.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 5 Apr 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  39. 5 Apr 2023Filings record

    Director or officer change

  40. 25 Jan 2023Insiders record

    RA CAPITAL MANAGEMENT, L.P. (ten percent owner) and 3 other(s) bought 1,923,076 shares of FULC ($25.0M) (dated 24 Jan 2023)

Showing the newest 40 of 100 entries; narrow the window or the kind of data to see older ones.

Not listed: 147 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001680581
Ticker
FULC
Domain
fulcrumtx.com
Employer name
FULCRUM THERAPEUTICS INC. (1 unverified)
Hq location
MA|CAMBRIDGE|02139 (1 unverified)
Lobbying client
fulcrum therapeutics
Name
Fulcrum Therapeutics, Inc.
Wikidata
Q104481162
  • DOL H-1B labor condition applications and PERM certifications42 data points10 Feb 2020 to 3 Apr 2023
  • Federal lobbying disclosures (LDA)4 records, 47 data points1 Sep 2022 to 30 Jun 2026
  • SEC Form 13F institutional holdings261 data points30 Sep 2019 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)134 records25 Jul 2016 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)476 data points31 Dec 2017 to 8 Nov 2026
  • SEC Form 4 insider transactions68 records, 208 data points22 Jul 2019 to 20 Jul 2026
  • FINRA short interest (twice monthly)521 data points31 Jul 2019 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3696 data points18 Jul 2019 to 20 Nov 2026